By: Benzinga
March 14, 2013 at 15:44 PM EDT
UPDATE: Aegis Capital Maintains China Biological Products at Buy, Raises PT on 4Q Earnings
Aegis Capital analyst Raghuram Selvaraju published a report on China Biological Products (NASDAQ: CBPO ) that maintained its Buy rating and raised the 15-Month price target from $22 to $28 per share. Aegis Capital reported that, “Compared to the previous quarters of 2012, 4Q 2012 revenue saw a dip due
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here